Anatara is seeking to partner with international pharmaceutical and consumer health companies for the commercialisation of its Gastrointestinal ReProgramming (GaRP) dietary supplement product which has been designed to address the primary underlying factors associated with human gastrointestinal conditions such as Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS), where there is a significant unmet need and market opportunity.